Working towards novel therapeutics to treat motor symptoms associated with Huntington’s disease.
GPR88 agonists to treat motor symptoms of Huntington’s disease.
Pandeia Therapeutics is an asset centric, VC funded biotech based in Oxford, UK. Our efforts are directed towards discovering and developing novel therapeutics to treat the motor symptoms associated with Huntington’s disease.
What We Do
Discovering and developing novel therapeutics to treat the motor symptoms associated with Huntington’s disease
About Us
Find out more about the team behind Pandeia Therapeutics.
The Science
Our approach to therapies for Huntington’s disease.
Latest News
All the latest company news, updates and press releases.
Contact Us
Get in touch with us to find more about what we do.
